News Hub | News Direct

Newsletter - How G Medical Innovations is transforming telehealth and mobile cardiac telemetry in 2024

G Medical Innovations Holdings Ltd

A revolutionary chronic care management system that empowers patients to take control of their health A suite of sensors, such as 1-lead ECG, SPO2, temperature, BP, and weight scale, that can be used by the patients at home and transmit their vital signs and other measurements to the cloud in real-time. Portals and Smartphone Apps for the patients and physicians, where they can view trends and history, perform video conferences, write prescriptions and meeting summaries, and receive alerts for any abnormality or symptom detected. A secured HIPAA compliance cloud-based platform where the data from the sensors are stored, analyzed, and shared securely. We are thrilled to introduce our new flagship product, the Prizma, an ecosystem that empowers patients to take control of their health and enables physicians to monitor their patients and improve outcomes. Prizma consists of the following components: Prizma has many benefits for both patients and providers. For patients, it can improve their quality of life, reduce hospital visits, and lower their healthcare costs. For providers, it can enhance their efficiency, accuracy, and productivity. It can also empower patients to take control of their medical conditions. Prizma ecosystem allows physicians to offer their patients RPM and RPT services, which are covered by CPT codes and, on the one hand, improve patients' treatment and, on the other hand, allow the clinic to generate additional revenue streamline. We are proud of our innovation and believe that Prizma is a game changer in the healthcare industry and in the lives of our patients. Our expanded telehealth network and partnerships We are also excited to share with you that we have expanded our telehealth network and partnerships with leading healthcare providers and insurers across the country. We now offer our telehealth solutions and mobile cardiac telemetry services to more than 100 million members and patients, covering a wide range of cardiac conditions and needs. Our telehealth solutions and mobile cardiac telemetry services are designed to provide convenient, accessible, and affordable care to our customers and patients. Our telehealth solutions and mobile cardiac telemetry services are proven to improve outcomes, reduce costs, and enhance quality of life. Facts you may not be aware of The Triple Analysis you need to know about, how our service enhances your patient care in extra 2 unique steps. Did you know that at the end of each MCT study, the entire report undergoes a double screening to detect events that the device's algorithm did not detect in real-time? At G Medical, this is our unique approach: An AI-based algorithm conducts the first screen and is then verified by certified cardiac technicians. On average, 16% more events are identified during the end-of-study screening. We are committed to you and your patients, and we triple-check each case. The outcome justifies our efforts. Leading the 4 th healthcare revolution with our investment in R&D, quality assurance, and regulations We are committed to investing in research and development to bring you the most cutting-edge solutions for home hospitalization and remote treatment. These are the core values of the 4th healthcare revolution, which we are proud to be part of. Our R&D team is constantly working on enhancing our flagship product, the Prizma eco-system, as well as developing new sensors and monitoring solutions that are not available today. Prizma is a smart portable device that can monitor vital signs, detect abnormalities, and alert medical professionals in real-time. It can also sync with our cloud-based platform, where we can store, analyze, and share the data securely. We are excited to share our R&D efforts with you, and we look forward to launching these new features soon. As our customer, you will be the first to use them and enjoy the benefits of being part of the 4th healthcare revolution. Our culture and team spirit Finally, we want to acknowledge and celebrate our culture and team spirit that makes us who we are. We have fostered a collaborative, diverse, and inclusive work environment that values and respects each and every one of our team members. We have welcomed new talent and expertise to our team and provided opportunities for learning and development for our existing staff. Our team receives ongoing training and education from leading industry instructors, which keeps them up-to-date and enables them to provide you with our well-known high-service standards. In addition, our company culture reflects our commitment to delivering our well-known personal, attentive, and flexible service to our customers. We respect your preferences, adapt to your requirements, and ensure your satisfaction throughout the process. To conclude, We know that you have alternatives, and we are truly grateful and honored to have you as our valued customer and partner in this journey. We look forward to serving you and meeting your needs in the coming year and beyond. If you want to learn more about our telehealth solutions and mobile cardiac telemetry services, please visit our website at https://gmedinnovations.com/ or contact our sales team at support.us@gmedinnovations.com. You can also follow us on LinkedIn: https://www.linkedin.com/company/g-medical-innovations/ for more updates and news. Sincerely, Dr. Yacov Geva CEO and President of G Medical Innovations G Medical Innovations Holdings Ltd. is a health care company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease, pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both health care providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing multi-channel patient-worn biosensors with algorithms, to generate real time analysis and transmission that captures electrocardiography data continuously, including QT syndrome prolongation detection. In addition, the Company is developing its wireless vital signs monitoring system, which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of independent diagnostic testing facility monitoring services and private monitoring services. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical Innovations is using forward-looking statements when it discusses: revenue growth and profitability in future periods; the launch of the Company’s CLIA lab in Austin, TX, the Company’s online store for its Prizma Monitoring Devices on Amazon Marketplace and the Company’s HTKs business and online stores; potential announcements with large homecare service companies and large distributors for devices and At Home Test Kits; and the Company’s plans to expand its line of monitoring products and services offered to patients, hospitals and clinics. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical Innovations could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties,, including those discussed under the heading “Risk Factors” in G Medical’s Innovations Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on May 16, 2023, and our other filings with the SEC, which are available on the SEC’s website, www.sec.gov. Except as otherwise required by law, G Medical Innovations undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Contact Details Rina Bar +972 54-724-0412 rinab@gmedinnovations.com Company Website https://gmedinnovations.com

January 05, 2024 03:17 AM Eastern Standard Time

Image

Align Surgical Practice Members Named to Influential Medical Advisory Roles

Align Surgical Associates

The California-based gender-affirming healthcare provider Align Surgical Associates Inc. (Align Surgical) announced today that two of its surgeons have been appointed to influential advisory roles by national medical societies. Align Surgical founder and CEO Thomas Satterwhite, M.D., has been named a contributing editor to Plastic and Reconstructive Surgery (PRS), the journal of the American Society of Plastic Surgeons (ASPS). Dr. Satterwhite was nominated for the role by the journal’s editorial leadership and confirmed this month by the full editorial board and the ASPS board of directors for a three-year term starting in January 2024. As a contributing editor, Dr. Satterwhite will serve as a peer reviewer on new research submissions and contribute his own writings, among other responsibilities. John Pang, M.D., F.A.C.S, will join the Guideline Development Panel of the Endocrine Society, the century-old organization at the forefront of hormone science and public health in the United States. This expert panel will spend two years developing and updating the Endocrine Society’s clinical practice guidelines on gender affirming care. During this time, this panel will meet, write and review evidence to rigorously develop and implement evidence-based practice-wide recommendations. “I am honored to join the editorial board of the leading journal in our field,” said Dr. Satterwhite, who is a board-certified plastic surgeon and Diplomate of the American Board of Plastic Surgery. “I congratulate Dr. Pang on his appointment to the Endocrine Society panel, a role that speaks to his considerable expertise. A key part of our vision for Align Surgical has been to make active research central to the practice. While this may be an unusual commitment for a private medical practice, I believe it is vital to achieve a deeper understanding of what is possible in the critical field of gender-affirming healthcare. We have a duty to pursue technical innovations and ultimately share our findings with our colleagues so that patient outcomes everywhere can improve. These national advisory opportunities are an extension of that commitment.” Thomas Satterwhite, M.D., is a board-certified reconstructive plastic surgeon and a Diplomate of the American Board of Plastic Surgery. Dr. Satterwhite completed his B.A. with honors, medical degree and plastic surgery residency at Stanford University in Palo Alto, CA. He specializes in all aspects of gender-affirming surgical procedures, including those for the face, body, chest and genital areas. Dr. Satterwhite is based at Align Surgical’s San Francisco office, serving patients from California and across the United States. John Pang, M.D., F.A.C.S., is a double board-certified plastic and reconstructive surgeon who specializes in complex genital, face and chest reconstruction, as well as aesthetic facial and body procedures. Dr. Pang received his medical degree from the John A. Burns School of Medicine at the University of Hawaii, Manoa. He completed a general surgery residency at Einstein Medical Center in Philadelphia, PA; a plastic and reconstructive surgery residency at the University of Pittsburgh in PA; and a transgender surgery/ plastic and reconstructive surgery fellowship at Mount Sinai Medical Center in New York, NY. Dr. Pang is based in San Francisco. * * * About Align Surgical Associates Align Surgical Associates was founded in 2018 with the mission of providing gender-affirming surgery to the transgender, non-binary and gender-diverse community with excellence, compassion and the belief that all people deserve to experience the freedom of living as their true selves. Align Surgical is one of the few interdisciplinary surgical practices in the United States that exclusively provides comprehensive gender-affirming care. Align Surgical’s surgeons in San Francisco and Los Angeles provide the full range of facial, body contouring, top and bottom surgeries and share a commitment to advancing innovation and research in their specialty fields. More information at alignsurgical.com. Media, please note: Visual assets, including photos and video, are available. To request an interview with experts from Align Surgical Associates, please contact Sean Dowdall at 415.286.7121 or Align@landispr.com. ### Contact Details Landis Communications Inc. Sean Dowdall +1 415-286-7121 Align@landispr.com Company Website https://www.alignsurgical.com/

January 04, 2024 06:01 AM Pacific Standard Time

Image

AGC Biologics Announces Plans for New Manufacturing Site in Yokohama Japan

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct a new manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan. The new site is a part of the CDMO’s strategic growth strategy to create more high-quality pharmaceutical development and manufacturing services in the Asia region that can help meet the global demand for biologics and advanced therapy medicinal products (ATMPs). The facility is expected to be operational in 2026. The new AGC Biologics Yokohama facility will offer pre-clinical through commercial services for mammalian-based protein biologics, cell therapies and messenger RNA (mRNA). The site will house multiple 2,000L single-use bioreactors and several 4,000L or larger reactors for mammalian cell culture services, making it one of Japan’s largest* sites for mammalian-based manufacturing capacity once complete. (*AGC estimates) AGC Biologics is building this facility thanks to a grant from the Japanese Ministry of Economy, Trade and Industry (METI) as part of the ministry’s initiative to develop biopharmaceutical manufacturing sites to strengthen vaccine production in the region ( announced in October 2022 ). The total investment for the AGC Biologics Yokohama site is expected to be approximately 50 billion Japanese yen ($350,500,000 USD) and once fully operational it will employ 400 people. “With an increased demand in this region for high-quality partners that have a history of clinical and commercial biopharmaceutical manufacturing, we are making this investment to offer developers the services they need, and strengthen our global CDMO network,” said Patricio Massera, Chief Executive Officer, AGC Biologics. “The new Yokohama facility will be a central location for innovators in Japan and across the Asia Pacific, offering scientific expertise, technical flexibility and needed services to support development and manufacturing at every critical stage.” The Yokohama facility is expected to significantly contribute to the needs of regional and global developers seeking biopharmaceutical development and manufacturing capabilities, in addition to further maximizing operational and supply chain efficiencies across AGC Biologics' global network. The company currently operates one site in the region, its Chiba facility, offering mammalian expression and microbial fermentation services. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs ten different facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients and agrochemicals. To learn more about AGC Biologics’ global network of services for protein biologics and cell and gene therapies, please visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

January 04, 2024 09:00 AM Eastern Standard Time

Dr. N. Krishna Reddy appointed CEO and Dr. Sten Vermund inducted to ACCESS Health International's Board of Directors

ACCESS Health International

HYDERABAD, INDIA - Media OutReach Newswire - 4 January 2024 - ACCESS Health International, a globally recognized health systems think tank and advisory group, today announced two important leadership transitions. Dr. N. Krishna Reddy, who has been leading the operations as President across Asia, Middle East, and North Africa, has been appointed Chief Executive Officer. Concurrently, the organization welcomes to its Board of Directors, Dr. Sten Vermund, Yale University Anna M.R. Lauder Professor of Public Health and a preeminent figure in pediatric medicine and infectious disease epidemiology. This transition follows the leadership of Dr. William Haseltine, the founder CEO and Chair, who will continue his invaluable contributions as Chair. Dr. Reddy's elevation to CEO marks a significant milestone in his illustrious career in healthcare and in his tenure with ACCESS Health International. As a distinguished senior cardiologist, Dr. Reddy has championed the cause of high-quality healthcare that is both affordable and accessible. His leadership has been instrumental in fostering collaborations, driving innovations, and expanding the organization's footprint across Asia. Notably, he co-founded CARE Hospitals in 1997, a chain of tertiary care establishments spanning six states in India. His entrepreneurial acumen and clinical expertise have been pivotal in shaping ACCESS Health's vision and strategies. "It is an honor to be assigned the new responsibility, more so in the times of emerging health challenges arising from the convergence of global crises. The strong foundation laid over the past 15 years of ACCESS Health will support my efforts to convert the challenges into opportunities and move closer towards our vision," Dr Reddy said on the occasion. Dr. Sten Vermund's appointment to the Board adds a layer of expertise and global perspective. Holding significant roles at the Yale School of Public Health, including his position as President of the Global Virus Network, Dr. Vermund's work has been transformative, especially in resource-limited settings. His groundbreaking research on HIV/AIDS, sexually transmitted infections, and more recently, COVID-19, underscores his commitment to combating infectious diseases. Furthermore, Dr. Vermund's innovative work on HIV-HPV interactions has catalyzed policy changes and inspired global health initiatives, making him an invaluable addition to ACCESS Health International. Dr. Vermund states, "ACCESS Health seeks to build local capacity and innovate in health system effectiveness in the regions of the world that do not have equitable healthcare access. I am most keen to assist in any way that I can as a member of its Board. In 2024 when we see so much strife and environmental threat in our world, the ACCESS mission is as critical as ever." ACCESS Health International Established in 2007 in Hyderabad, India, ACCESS Health International has become a leading organization in health systems research and innovations. As a non-profit organization, ACCESS Health partners with governments, the private sector, and researchers globally. It operates from four global offices in New Delhi, Hyderabad, Singapore, and Dubai, focusing on providing quality and affordable healthcare for all. The organization emphasizes a holistic approach to health systems, covering governance, payers, providers, community, and information systems. Notable initiatives include technical assistance to Indian state governments for the Pradhan Mantri Jan Arogya Yojana (Government of India's flagship public health insurance scheme), the Global Learning Collaborative for Health Systems Resilience and the Asia-Pacific Cardiovascular Disease Alliance. Through efforts such as the India Health Systems Collaborative, ACCESS Health promotes knowledge sharing and seeks to enhance healthcare systems globally. With Dr. Reddy at the helm as CEO and Dr. Vermund bringing his extensive expertise to the Board, ACCESS Health International is poised for an era of growth and impact. The organization's commitment to community-centric, inclusive healthcare policies, coupled with its dedication to fostering innovations and collaborations, will solidify its position as a global leader in health systems research, capacity building, advocacy and implementation. For comprehensive details on ACCESS Health International's initiatives, partnerships, and team, please visit www.accessh.org. Contact Details ACCESS Health International Uma Aysola uma.aysola@accessh.org

January 04, 2024 01:58 AM Eastern Standard Time

News Release

hVIVO secures £6.3 million challenge contract

hVIVO PLC

hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candidate using the hVIVO Human Rhinovirus Human Challenge Study Model. The Phase 2a clinical trial is designed as a randomised, double-blinded, placebo-controlled human challenge study and will be conducted at hVIVO's advanced quarantine facilities in Canary Wharf. The primary objective of this study is to assess the impact of the antiviral candidate on viral load, safety, tolerability, and prophylactic antiviral activity against Human Rhinovirus (HRV) infection in various groups of healthy volunteers. Catchpole explained that the study is scheduled to begin in the second half of 2024, with revenue recognition spread across 2024 and 2025. As part of the study, hVIVO will recruit healthy volunteers who will be subjected to controlled HRV infection. The biotechnology client recognizes the value of human challenge studies in rapidly generating early human efficacy data, which has the potential to significantly enhance the clinical asset's overall value. Catchpole says the contract underscores hVIVO's expertise in conducting human challenge studies and its growing role in helping pharmaceutical and biotechnology companies evaluate the effectiveness of their antiviral treatments. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

January 02, 2024 01:23 PM Eastern Standard Time

Video

Centre for Neuro Skills Announces David Harrington as New CEO; CNS Founder Mark Ashley Named Executive Chairman of the Board

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of traumatic and acquired brain injury rehabilitation services, today announced David Harrington as its new Chief Executive Officer. Harrington, who previously was CNS’s President and Chief Operating Officer, expands his role at CNS and assumes the CEO position from founder Dr. Mark Ashley. Ashley will continue as full-time Chairman of the Board and remain actively involved in directing the company’s vision and business strategy. “David Harrington and I have worked side-by-side at the Centre for Neuro Skills for more than 24 years, and he is the right executive to lead CNS in its next phase of growth,” said Ashley. “As Executive Chairman, David has my full support while I continue to provide vision, organizational growth and strategic development for CNS.” CNS has provided neurorehabilitation therapy to those with traumatic brain injury (TBI) and stroke since 1980. CNS has seven clinics – including Texas locations in Austin, Dallas, Fort Worth, Houston, and California locations in Bakersfield, Los Angeles, and San Francisco. As CEO, Harrington will oversee innovative strategies for heightening awareness of brain injury, improving the efficacy, efficiency, and quality of healthcare interventions. In addition to clinical treatment, he will focus on organizational growth, strategic development and management, and marketing and sales. “Mark has been a mentor and a friend to me for several decades now, and I feel like I'm well positioned to carry on his legacy,” Harrington said. “Mark is more than the founder of CNS; he is the patriarch of this family-owned and multigenerational company. I am grateful for the trust he has placed in me and excited to lead a company with such a deep history.” Harrington began working in the field of post-acute brain injury rehabilitation in 1993. He is a Registered and Licensed Occupational Therapist with advanced practice in hand therapy and physical agent modalities. His career has included being a Therapist, Clinical Case Manager, Quality Manager, and Director of Operations. David studied Occupational Therapy at San Jose State University prior to obtaining his Master of Business Administration at California State University in Bakersfield. He has been a Certified Brain Injury Specialist and Trainer (CBIST) since 2006. Harrington routinely presents to medical and academic groups regarding the neurology and function of vision and perception after acquired brain injury, disease management of brain injury, and ethics in healthcare. He is also an adjunct instructor at the School of Business at California State University Bakersfield, where he teaches Operations Management, Business Ethics, Stakeholder Management, Business Data Analysis, Organizational Behavior, and Diversity Management. He currently serves on the Board of Directors of the Brain Injury Association of America. Harrington is a member of the Kern County Concussion Consortium. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: https://www.neuroskills.com/, Facebook, Twitter, LinkedIn, YouTube, Instagram. For a video overview of CNS, visit: https://youtu.be/Jwqve9gWtEw Media please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415-766-0927 or CNS@landispr.com # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

January 02, 2024 08:01 AM Pacific Standard Time

Image

News Release

Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman shares groundbreaking news during an interview with Steve Darling from Proactive. The company has achieved highly positive results in their clinical trial targeting Fibromyalgia, a chronic pain disorder affecting approximately 10 million Americans and for which satisfactory treatments are often lacking. TNX 102 SL, Tonix's drug candidate, demonstrated remarkable efficacy in the second phase three clinical trial. The primary pain endpoint achieved an exceptionally low p-value of 0.00005. What's even more promising is that TNX 102 SL is a non-opioid medication with no recognized addictive potential. In addition to addressing pain, the drug also effectively tackled other Fibromyalgia symptoms such as fatigue and sleep disturbances. Lederman informed Proactive that the company's next steps involve filing a new drug application (NDA) for FDA approval. They anticipate a pre-NDA meeting scheduled for the first half of 2024. This groundbreaking development places Tonix Pharmaceuticals at the forefront of Fibromyalgia treatment innovation, providing hope to millions of individuals suffering from the condition. Further updates on this transformative drug are eagerly anticipated in 2024. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

January 02, 2024 06:08 AM Eastern Standard Time

Video

Shaurya Infosoft Unveils Their Latest PR CMS Platform 'Spark Metro'

Spark Metro PR

Leading innovator in technological solutions, Shaurya Infosoft, is pleased to announce the official launch of "Spark Metro," a cutting-edge platform for PR CRM (Press Release - Customer Relationship Management) that aims to reform and strengthen the press release distribution services sector. In the domain of media outreach, the innovative Spark Metro platform stands out for its remarkable capabilities that enable companies to seamlessly communicate with their target audience. This state-of-the-art platform is set to completely change how businesses handle and distribute press releases, promoting a more efficient and successful communication process. Key Features of Spark Metro:1 Easy to Operate User Interface: Spark Metro boasts of its easy-to-operate and user-friendly interface. It ensures both experienced and newcomers can navigate the platform hassle-free. The design enhances the user experience on the platform and makes the press release submission work much easier. 2. Targeted Distribution: The algorithms help in advanced audience targeting. The Spark Metro platform helps its users reach the desired audience within the stipulated time frame. The custom list to distribute the press release ensures that the press release gets delivered to the proper journalist, social media influencer or the desired media outlet for generating a meaningful impact. 3. Media Relationship Management: The platform has a comprehensive CRM system specifically designed for Press Release professionals. This CRM system helps manage and grow relationships with journalists and media contacts, enabling long-term connections for sustained mutual growth. 4. Real-time Analytics: In the analytic section, users can gain valuable insights into press release performance with real-time analytics. They can track engagement, monitor the reach of their press release and assess the impact of each release to modify future communication strategies. 5. Multimedia Integration: Spark Metro platform supports various multimedia elements, allowing users to enhance their press releases with images, videos, infographics and other rich media. It helps to capture audiences with compelling content to make a long-lasting impression. 6. Security and Compliance: Spark Metro understands the need to secure sensitive user information and thus incorporates robust security features in compliance with industry standards. Users can rely on the platform and share the data without compromising it, as it safeguards all the data and communications. The founder and CEO of Shaurya Infosoft expressed enthusiasm about the platform's launch, stating, "Spark Metro is a huge breakthrough in the press release distribution industry. We think firms may improve their media outreach efforts and forge closer ties with their target audience by offering a complete, easy-to-use solution." Shaurya Infosoft invites businesses, Press Release agencies, and communication professionals to experience the power of Spark Metro firsthand. The platform is now available for sign-up, and interested parties can visit www.sparkmetro.com for more information. About Shaurya Infosoft: Shaurya Infosoft was born to offer comprehensive software solutions and has expanded its scope across the globe. The journey marks continuous evolution and runs on a strong commitment to delivering excellence and embracing the latest technology. The vision of Shaurya Infosoft: Envision Shaurya Infosoft as a stable and globally recognized IT services provider. Most sought-after web development organization An organization that acts as a brand promoter for others by developing the corporate website's message. The mission of Shaurya Infosoft: Provide well-programmed and carefully coded user-friendly websites Simplify the lives of clients through user-friendly products and services. Foster long-term, mutually beneficial professional associations. Focus on making the client's brand image stand out in their industry. Core Values of Shaurya Infosoft: Honesty and Sincerity Creative Innovations Emphasis on High Customer Satisfaction Perpetual Learning and Development Respect for Time and Value for Money About Spark Metro: Spark Metro is a leading player in the field of press releases. It offers innovative solutions to empower brands to share their message effectively in a rapidly moving digital world. With a commitment to excel, emphasis on high customer satisfaction, and dedication to staying up to date with industry standards, Spark Metro is here for your success in the digital age. For media inquiries, please contact: Contact Number: +1 (302) 597-6768 Email Id: support@sparkmetro.com Contact Details Anoj Kumar +1 302-597-6768 info@shauryainfosoft.com

December 30, 2023 05:36 AM Eastern Standard Time

Image

Shaurya Infosoft Introduces 'Spark Metro,' a Revolutionary PR CRM Platform.

Spark Metro PR

Shaurya Infosoft, a leading company and innovator in the realm of technology solutions, proudly announces the launch of 'Spark Metro,' a cutting-edge press release Customer Relationship Management (PR CRM) platform that is designed to change the whole outlook of press release distribution. Built on a base of innovation and driven by a commitment to excel, Spark Metro is designed to elevate the art of press release distribution, providing businesses with a powerful tool to enhance their communication strategies and outreach efforts. This platform introduces many advanced features, seamlessly combining efficiency, customization, and advanced analytics to meet the evolving needs of today's dynamic media landscape. Key Features of Spark Metro: 1. Intelligent Targeting: Spark Metro uses advanced mechanisms and algorithms to identify the approach of the most relevant journalists, editors, social media influencers, media outlets, etc, to ensure that the press release reaches the specified audience and leaves the maximum targeted impact. 2. Customization and Personalization: The Spark Metro empowers users to customize the press release according to industry standards; it further allows for personalized communications that align with the recipients of the press release. Starting from the tailored marketing pitches to a customized list of media attachments, Spark Metro trusts all the efforts of personalization in the hands of press release experts. 3. Real-Time Analytics: The Spark Metro offers real-time performance metrics to the users. Users can keep track of various parameters such as engagement metrics and media coverage, measure the effectiveness of the communication strategy applied, and help make data-driven decisions. 4. Multi-Channel Distribution: Spark Metro provides seamless distribution across a wide range of platforms, including traditional media outlets, online publications, and various social media platforms. This diversity of distribution enables high coverage and larger visibility on the global platform. 5. Collaborative Workspaces: The innovative PR CRM Platform fosters teamwork, allowing smooth and effective communication within the team. Users can share drafts, exchange feedback and collaborate with the clients to enhance the efficiency within the CRM. The Media Manager at Shaurya Infosoft stated- "Spark Metro represents an important leap forward in the press release distribution industry. When effective communication is essential, the Spark Metro platform empowers businesses to connect with the target market audience in a highly personalized and impactful manner. We believe that - Spark Metro will redefine how press releases are crafted, targeted, and delivered, setting a new standard for PR CRM platforms in the market. About Shaurya Infosoft: Shaurya Infosoft was born to offer comprehensive software solutions and has expanded its scope across the globe. The journey marks continuous evolution and runs on a strong commitment to delivering excellence and embracing the latest technology. The vision of Shaurya Infosoft: Envision Shaurya Infosoft as a stable and globally recognized IT services provider. Most sought-after web development organization An organization that acts as a brand promoter for others by developing the corporate website's message. The mission of Shaurya Infosoft: Provide well-programmed and carefully coded user-friendly websites Simplify the lives of clients through user-friendly products and services. Foster long-term, mutually beneficial professional associations. Focus on making the client's brand image stand out in their industry. Core Values of Shaurya Infosoft: Honesty and Sincerity Creative Innovations Emphasis on High Customer Satisfaction Perpetual Learning and Development Respect for Time and Value for Money About Spark Metro: Spark Metro is a leading player in the field of press releases. It offers innovative solutions to empower brands to share their message effectively in a rapidly moving digital world. With a commitment to excel, emphasis on high customer satisfaction, and dedication to staying up to date with industry standards, Spark Metro is here for your success in the digital age. For media inquiries, please contact: Contact Number: +1 (302) 597-6768 Email Id: support@sparkmetro.com Contact Details Anoj Kumar +1 302-597-6768 info@shauryainfosoft.com

December 30, 2023 05:30 AM Eastern Standard Time

Image

Healthcare

Newsletter - How G Medical Innovations is transforming telehealth and mobile cardiac telemetry in 2024

Align Surgical Practice Members Named to Influential Medical Advisory Roles

AGC Biologics Announces Plans for New Manufacturing Site in Yokohama Japan

Dr. N. Krishna Reddy appointed CEO and Dr. Sten Vermund inducted to ACCESS Health International's Board of Directors

hVIVO secures £6.3 million challenge contract

Centre for Neuro Skills Announces David Harrington as New CEO; CNS Founder Mark Ashley Named Executive Chairman of the Board

Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL

Shaurya Infosoft Unveils Their Latest PR CMS Platform 'Spark Metro'

Shaurya Infosoft Introduces 'Spark Metro,' a Revolutionary PR CRM Platform.